GlycoKnow Colon is a blood-based laboratory-developed test (LDT) designed to assess the presence of adenomas with high-grade dysplasia or colorectal cancer by harnessing the power of the immune system.
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, leading to over 50,000 deaths annually. With appropriate and timely screening, CRC is highly preventable and treatable, and early detection is critical to improving patient outcomes.
Unfortunately, screening rates remain below national targets, exacerbated by the lack of convenient and effective options for patients.
Once available, a single blood draw will be able to put patients on the path to receiving care before a tumor has developed, and when intervention is most optimal.
Single-tube blood draw
Pre-cancer & early stage cancer detection
Rapid 10-day turnaround time
By clicking submit, you confirm that you are a U.S. resident and you agree to receive information about InterVenn, including information about any of its current or future products or product candidates or disease state information, and you acknowledge that you have read and agree to the Terms of Use and Privacy Policy. All personal information will be kept confidential and will not be shared with any parties other than InterVenn, its affiliates and their designated agents.
View our privacy policy.
GlycoKnow Colon is intended to be complementary to—and not a replacement for—current recommended colorectal cancer testing methods.
Proteins undergo a variety of post-translational modifications. Glycosylation, the enzymatic attachment of sugar structures, is one of the most abundant and critical of these modifications, impacting more than 70% of proteins, altering their function and structure2. Protein glycosylation is a critical feature associated with tumor development, including colorectal cancer.
GlycoKnow Colon unlocks the glycoproteome using novel high-throughput mass spectrometry technologies paired with AI-powered data processing and machine learning. It measures both the abundance of and the variation in glycosylation profiles of glycoproteins in serum isolated from blood, providing an unprecedented view into the systemic response of the body to the progression of colorectal cancer.
Learn MoreGlycoKnow Colon monitors the body’s response to disease progression, enabling pre-cancer detection. Other tests rely on material shed by the tumor, missing early stage.
For illustrative purposes only
GlycoKnow Colon was developed utilizing our proprietary technology platform, GlycoVision. We offer biomarker development services that enable the generation of new disease insights and the discovery of a robust pipeline of biomarkers for early disease detection, response prediction, disease prognosis, and therapeutic monitoring.
1. American Cancer Society. Colorectal Cancer Facts & Figures 2023-2025. Atlanta: American Cancer Society, Inc. 2022.
2. An H.J., Froehlich J.W., Lebrilla C.B. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr. Opin. Chem. Biol. 2009;13:421–426. doi: 10.1016/j.cbpa.2009.07.022.
InterVenn Biosciences’ clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing, and complies with College of American Pathologists (CAP) Proficiency Testing requirements. The GlycoKnow Colon test is developed, and its performance characteristics determined, by InterVenn Biosciences. The GlycoKnow Colon test has not been cleared or approved by the U.S. Food and Drug Administration.
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
